Clinical Research Directory
Browse clinical research sites, groups, and studies.
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Summary
This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.
Official title: A Phase Ib/II Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Combination With ZG005 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma(NEC)
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
350
Start Date
2025-09-23
Completion Date
2027-09
Last Updated
2026-01-05
Healthy Volunteers
No
Interventions
ZG006
ZG006 will be administered as an intravenous (IV) infusion.
ZG005
ZG005 will be administered as an intravenous (IV) infusion.
Locations (1)
Sun Yat-sen University Cancer Center
Guanzhou, Guangdong, China